The ancient Chinese text of the Zhuangzi teaches us to reject entrenched values – and treasure the diversity of humanity
The Zhuangzi, an ancient Chinese Daoist text written by the philosopher known by the same name, has a lot to say about people who are considered 'disabled'. This is interesting in itself, as parts of it were written around the 4th century BCE, when only the privileged could read and write.
Why would the authors of this text, men of privilege, be interested in people who were considered at the time to be 'less than normal'?
The answer relates, at least in part, to the fact that the text was critical of how its society promoted and prioritised the 'valuable' or 'useful', and what was regarded as important to humanity.
Within such a society, whatever – or whoever – falls short of the accepted standards is seen in demeaning ways. But the Zhuangzi rejects this way of thinking.
So how might we put some of these ideas into practice today?
The Zhuangzi tells the story of a wondrous tree, so large that its canopy provided shade for thousands of oxen. The tree only became this large because its wood was deemed to be 'useless' for any human project. Therefore, it was left alone and allowed to grow into its magnificent size.
This story shows how easy it is for us to adopt entrenched values. Are we guided too much by what society tells us is 'useless'? It allows us to turn the tables on our own assumptions and challenge our thinking of what 'normal' and 'useful' means. This is reflective of Daoism more broadly, which advocates for diversity in how we think about humanity and human achievements.
Daoism resists what would today be considered an ableist approach to life. It teaches us that looking at life through an ableist lens only leads to negativity about those who are deemed 'not good enough'. Such an approach looks for how people are deficient, rather than how they are capable.
The Zhuangzi's point is not that we cannot celebrate excellence. Rather, it champions the richness of life by showing that people can be excellent in many different ways. Instead of telling us how to fix people's medical and physiological conditions, it prompts us to reflect on the shallow attitudes of those who see others as 'disabled', who want to draw attention to what some people lack, rather than what they might have.
There isn't a word in the Zhuangzi that means 'disability'. Rather, the ancient text uses storytelling and exaggerated language to try to show how society sees some people in derogatory ways. Stories about 'sad horsehead humpback' or 'hunchback limpleg' show that these are not labels that the men were born with; they were given to them by a society that wrongly prides itself on 'normalising' able-bodied people.
Through these stories, we learn that sometimes the word 'disability' is used unfairly to define people, so that our interactions with them are determined by the label.
As the Zhuangzhi shows, life is too important for us to take a one-size-fits-all approach to it. The philosophy encourages us to embrace the richness of life by appreciating its diversity.
Karyn Lai is a professor of philosophy in the faculty of arts, design and architecture, University of New South Wales
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Reuters
an hour ago
- Reuters
China's Sciwind's GLP-1 shows similar weight loss to Novo's Wegovy, study finds
June 21 (Reuters) - Overweight patients given an experimental weight loss drug being developed by China's Sciwind Biosciences lost an average of 10% to 15% of their body weight, roughly in line with results from a similar drug sold by Novo Nordisk ( opens new tab, according to a late-stage study published on Saturday. The drug, called ecnoglutide, belongs to a class of drugs that include Novo's Wegovy called GLP-1 receptor agonists, which work by helping control blood sugar levels and triggering a feeling of fullness. "It's going to be competitive," said Dr. Tricia Tan of Imperial College London, who wrote a piece accompanying the data which appeared in medical journal The Lancet. Tan said additional GLP-1s on the market could potentially drive prices down and improve access globally. "It's great to have competition in the market. It's been extremely frustrating - I work in the National Health Service and patients are not getting access to these drugs." Patients have seen even better results with Eli Lilly's (LLY.N), opens new tab Zepbound, which stimulates GLP-1 as well as a second gut hormone called GIP. More than 20% weight loss was reported in clinical trials. According to the Sciwind Phase 3 study, 499 patients were given 1.2 mg, 1.8 mg or 2.4 mg of ecnoglutide as a subcutaneous injection once weekly for 48 weeks, with 165 patients assigned to receive a placebo. The study was conducted at 36 medical centers across China. The patients who received the 1.2 mg dose lost an average of 9.9% of their body weight after 48 weeks, and those who received the 1.8 mg dose lost an average of 13.3% of their body weight. Patients on the 2.4 mg dose lost an average of 15.4% of their body weight. The patients on placebo lost an average of 0.3% of their body weight over the period. The side-effect profile is not significantly different from the other weight loss drugs. Many of the patients given ecnoglutide experienced decreased appetite and gastrointestinal problems, including diarrhea, nausea and vomiting, the study authors wrote.
The Sun
12 hours ago
- The Sun
Model dies after ‘milk injection' from the ‘Godfather of Liposuction' in attempt to cure her chronic insomnia
A MODEL has died after getting a "milk injection" from the "Godfather of Liposuction". Cai Yuxin - who boasted tens of thousands of followers online - was desperately seeking any treatment to cure her chronic insomnia in Taiwan. 4 4 4 The 40-year-old model got a "milk injection" at a clinic in Taipei - a short-acting intravenous anaesthetic called propofol used for sedation and anaesthesia in hospital settings. The killer injection was administered by Taiwan's "Godfather of Liposuction" - Wu Shaohu, the clinic's director. After Cai was injected, the liposuction Godfather then reportedly left the clinic - leaving only an assistant with no nursing licence to monitor the model's condition. Local media reports that the equipment may not have been set up properly, leading to an increase in the drip rate of the injection. This therefore caused a larger dose of the anaesthetic to be delivered in a short time frame. Cai - who had over 32,000 social media followers - tragically suffered cardiac and respiratory arrest. The assistant managed to reach Wu on a video call, who guided him in performing CPR on Cai. But by the time the clinic director desperately scrambled back to the clinic, the model was no longer breathing and her heart had stopped. She was then rushed to hospital for emergency treatment, where she remained in a coma for 19 days - but her family later decided to stop her life support. Local authorities have launched a probe into Wu on potential charges of causing serious injury due to negligence and violating the Medical Care Act. The Ministry of Health and Welfare in Taiwan classifies propofol as a Schedule IV controlled substance, under the conditions that it is only administered by those qualified to do so under appropriate monitoring. Taiwanese anaesthesiologist Lai Xianyong stressed how propofol is a strictly regulated medication and clinics like Wu's that use it unlawfully to treat insomnia are in breach of medical ethics. Lai said: "Similar incidents occur every year. It's truly deplorable. "Medical personnel providing such services without proper airway management training are placing patients' lives in serious jeopardy." Tributes for Cai from her tens of thousands of followers have been pouring in. One person said on social media: "This is undoubtedly murder. I hope the police swiftly identify those responsible for her death and bring them to justice." Another commented: "Rest in peace. "Thank you for gracing our world – we will miss you." 4
The Independent
a day ago
- The Independent
Breast cancer survivors may have a lower risk of Alzheimer's disease, experts say
Could breast cancer survivors have a lower risk of Alzheimer's disease South Korean researchers say breast cancer survivors have an 8 percent lower risk of developing the condition compared to people without cancer, despite commonly-held concerns about cognitive decline following treatment. 'We found a slightly lower risk of [Alzheimer's] among breast cancer survivors, in line with several previous studies and a meta-analysis,' the authors wrote in a study published Friday in the journal JAMA Network Open, the open-access journal of the American Medical Association. 'This suggests that standard breast cancer treatments, including radiation therapy, may not increase and may even reduce Alzheimer's dementia risk in the short term,' Seoul National University Dr. Su-Min Jeong, who led the study, told AuntMinnie. 'Clinicians can use this evidence to reassure breast cancer patients concerned about their cognitive health.' The researchers also found no association between the risk for Alzheimer's and treatment with chemotherapeutic agents. 'An increased risk of dementia in patients with head and neck cancer treated with radiation therapy was noted. However, the risk of AD could differ, depending on the dose of radiation and site of exposure,' they explained. To reach these conclusions, they looked at the data from more than 70,000 patients who underwent breast cancer surgery between the first day of January 2010 and the last day of December 2016. The data was collected by the Korean National Health Insurance Service. Participants were grouped with healthy age-matched controls at a one-to-three ratio. The women underwent an average follow-up of 7.3 years. Among the participants, 1,229 cases of Alzheimer's were detected. Breast cancer survivors showed a slightly lower risk of developing Alzheimer's compared with cancer-free women. The trend was especially applicable to women aged 65-and-up. 'However, landmark analyses found that this lower risk did not persist beyond five years of survival. Cancer treatment with radiation therapy was associated with reduced risk of [Alzheimer's] among survivors,' they wrote. They say that further research is needed to assess the long-term risk of Alzheimer's disease in breast cancer survivors. Previous research from researchers at the University of Pittsburgh also found that hormone modulating therapy used for the treatment of breast cancer was associated with a 7 percent lower risk of developing Alzheimer's disease and related dementias later in life, and that some women may be at a higher risk than others. The South Korean researchers noted that cytotoxic chemotherapy has been recognized as a cause of cognitive decline called chemobrain in cancer survivors, referring to thinking and memory issues after treatment. Researchers added that their findings suggest that this treatment does not directly lead to Alzheimer's disease.
